Welcome to the 474th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days. It's a small newsletter as it's the week before the annual meeting, and I have limited time to put this together.
The highlights of this week's edition are four randomised controlled trials: firstly, the preprint of the REMAP-CAP IL-6 receptor anatgonists domain; secondly, another tocilizumab trial, this time in a more general population of patients hospitalized with Covid-19 pneumonia; thirdly, early high-titer plasma therapy to prevent severe Covid-19 in older adults; and finally, pulsed intravenous methylprednisolone in patients hospitalised with severe COVID-19.
There will be lots of activity around the meeting this week, starting with the release of the programme tonight. Registration, the release of the livestream url and other information is also due imminently.
Until next week